MedTrace Logo

Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases

NCT04723069 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2023-04-04

No results posted yet for this study

Summary

Randomized, double blind and positive-controlled clinical trial to assess the efficacy and safety of Fuke Qianjin Capsule compared to Doxycycline Hyclate Tablet in patients with mild to medium PID and its sequalae.

Conditions

  • Pelvic Inflammatory Disease

Interventions

DRUG

Control Group

metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.

DRUG

Test Group

metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.

Sponsors & Collaborators

  • Zhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou, China

    collaborator UNKNOWN

  • Center for bioequivalence studies and Clinical Research (CBSCR), ICCBS, University of Karachi

    collaborator UNKNOWN

  • University of Karachi

    lead OTHER

Principal Investigators

  • Professor Dr. Muhammad Raza Shah · Center for bioequivalence studies and Clinical Research (CBSCR), ICCBS, University of Karachi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-21
Primary Completion
2022-03-11
Completion
2022-03-11

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723069 on ClinicalTrials.gov